<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01141296</url>
  </required_header>
  <id_info>
    <org_study_id>Feno-01</org_study_id>
    <nct_id>NCT01141296</nct_id>
  </id_info>
  <brief_title>Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis</brief_title>
  <official_title>Randomized Controlled Study of Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the combination of ursodeoxycholic acid (UDCA)
      and fenofibrate is more effective than UDCA alone in the treatment of primary biliary
      cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of funding
  </why_stopped>
  <start_date>April 2011</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum alkaline phosphatase level</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms - quality of life</measure>
    <time_frame>one year</time_frame>
    <description>Quality of life will be evaluated throught the NIDDK questionnaire at entry and end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptoms - pruritus</measure>
    <time_frame>one year</time_frame>
    <description>Pruritus will be evaluated through a visual analogue scale and the 5-D questionnaire, both applied at entry and end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptom -fatigue</measure>
    <time_frame>one year</time_frame>
    <description>fatigue will be evaluated through the Fatigue Impact Scale applied at entry and end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interleukin 1</measure>
    <time_frame>one year</time_frame>
    <description>IL-1 will be measured from stored serum collected at entry and end of study. This will be measured by Beadlyte Human Multicytokine Detection system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interleukin 6</measure>
    <time_frame>one year</time_frame>
    <description>IL-6 will be measured from stored serum collected at entry and end of study. This will be measured by Beadlyte Human Multicytokine Detection system.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenofibrate</intervention_name>
    <description>fenofibrate 200 mg PO daily for 1 year</description>
    <arm_group_label>Fenofibrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo pill identical to active drug will be given PO once a day for 1 year</description>
    <arm_group_label>sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 21 and ≤ 75 years old

          2. Established diagnosis of PBC and positive AMA

          3. Previous treatment with UDCA 13-15 mg/kg/day for at least 1 year

          4. Incomplete response to UDCA defined as serum ALP ≥ 2 times the upper limit of normal
             on two separate measurements despite at least 1 year of therapy with UDCA

          5. Female patients of childbearing age need a negative pregnancy test performed within 7
             days of enrollment, and need to be on adequate contraception throughout the study
             period

          6. Signed informed consent after careful review of information and study details

        Exclusion Criteria:

          1. Hypersensitivity to fenofibrate

          2. Administration of the following drugs at any time during the 3 months prior to
             screening for the study: methotrexate, colchicines, azathioprine, systemic steroids.

          3. Prisoners and institutionalized subjects, pregnant or nursing women

          4. Anticipated need for liver transplantation within one year (estimated 1-year survival
             &lt;80% as predicted by the Mayo risk score).

          5. Recipients of liver transplantation

          6. Recurrent variceal hemorrhage, uncontrolled encephalopathy or refractory ascites

          7. Co-existing liver diseases such as acute or chronic viral hepatitis, alcoholic liver
             disease, choledocholithiasis, autoimmune hepatitis, biopsy-proven non-alcoholic fatty
             liver disease, Wilson's disease and hemochromatosis

          8. Acute or chronic renal failure, defined as GFR &lt; 60 ml/min

          9. Known history of cholecystitis with intact gallbladder

         10. History of, or known high risk for, venous thromboembolism

         11. Current use of warfarin or statins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Levy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2010</study_first_submitted>
  <study_first_submitted_qc>June 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2010</study_first_posted>
  <last_update_submitted>March 31, 2014</last_update_submitted>
  <last_update_submitted_qc>March 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Cynthia Levy</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

